Related Experiment Videos

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the

Antonio Nicolucci1, Giorgia De Berardis, Michele Sacco

  • 1Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale, 66030 S. Maria Imbaro (CH), Italy. nicolucci@negrisud.it

European Heart Journal
|July 3, 2007
PubMed

Insights

Guidelines on aspirin for primary prevention of cardiovascular disease in diabetes patients differ significantly between the US and Europe. Evidence suggests aspirin

Area of Science:

  • Cardiology
  • Endocrinology
  • Preventive Medicine

Background:

  • Recent guidelines from European and US scientific societies offer conflicting recommendations on aspirin use for primary prevention of cardiovascular disease (CVD) in individuals with diabetes.
  • Divergent expert opinions highlight a lack of consensus regarding aspirin's role in managing CVD risk in this population.

Purpose of the Study:

  • To analyze the discrepancies in current guidelines regarding aspirin for primary CVD prevention in diabetes patients.
  • To evaluate the existing evidence on aspirin efficacy and safety in individuals with diabetes.
  • To address the uncertainty surrounding aspirin therapy for CVD primary prevention in diabetes.

Main Methods:

  • Comparative analysis of European and US guidelines on aspirin for primary CVD prevention in diabetes.
  • Review of existing scientific literature and clinical trial data on aspirin in diabetic populations.
  • Assessment of the evidence base for current recommendations.

Main Results:

  • US guidelines recommend aspirin for primary prevention in individuals over 40 or with risk factors.
  • European guidelines omit aspirin for myocardial infarction/CVD death prevention but suggest it for stroke prevention.
  • Evidence indicates substantially lower aspirin efficacy in patients with diabetes compared to those without.

Conclusions:

  • Current recommendations appear based on extrapolations rather than comprehensive data reviews.
  • Existing trials are dated and may not reflect current cardiovascular risk management strategies.
  • Significant uncertainty exists regarding the benefit-risk balance of aspirin therapy in diabetes, impacting clinical practice and research.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...